Information  X 
Enter a valid email address

Renalytix AI PLC (RENX)

  Print      Mail a friend

Tuesday 19 November, 2019

Renalytix AI PLC

RenalytixAI attending City Event for Kidney Health

RNS Number : 8133T
Renalytix AI PLC
19 November 2019
 

Renalytix AI plc

("RenalytixAI" or the "Company")

 

RenalytixAI participating in Capital Markets Day for Kidney Health

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it is participating in a London based event focused on Kidney Health that will bring together senior officials from leading health agencies, innovators in the area of kidney health and investors focused on Lifesciences and medical technology.

 

The event is being led by the American Society of Nephrology, supported by Stifel, N+1 Singer and the London Stock Exchange, and includes a key note address from Barbara Murphy, MD, Chair of the Department of Medicine and Dean for Clinical Integration and Population Health at the Icahn School of Medicine at Mount Sinai, New York.

 

The full agenda can be viewed here: 

 

http://www.rns-pdf.londonstockexchange.com/rns/8133T_1-2019-11-18.pdf

 

One of the greatest drivers of health care cost today is patients whose kidney disease is not diagnosed in time and face kidney failure and unplanned transition to dialysis. Each year kidney disease kills more people than breast and prostate cancer1.

 

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

 

 

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison

 

 

 

N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen
/ Mia Gardner (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

       

 

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have kidney disease.  It is reported that 9 out of 10 adults with chronic kidney disease do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD2. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer.  Every day 13 patients die in the United States while waiting for a kidney transplant.

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

 

Notes

1 https://www.ncbi.nlm.nih.gov/pubmed/30738630

2 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRABIBDBCDBBGCI

a d v e r t i s e m e n t